Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
EntrestoⓇ delivering strong double-digit growth in all geographies
GROWTH
Entresto
Sales evolution
USD m, % cc
Ex-US
US
US weekly TRX1
Total prescriptions (000)
110
100
+32%
90
80
1,399
70
28
1,093
60
695
50
551
40
40
30
20
704
542
20
Strong Q1 momentum, outpacing market²
US: NBRX +30% vs PY, ~1.3m TRx in Q11
EU: Continued growth in HFrEF
China/Japan: Significant contribution from HTN³
Confidence in future growth4
Expect further penetration in HFrEF
(2/3 eligible patients still on prior SoC)
Robust guideline position 5 (US/EU)
CHMP positive opinion for pediatric HF6
China/Japan: Launch momentum in HTN, inclusion
in 2023 China HTN guideline as 1L option
Q1 2022
10
0
Q1 2023
July 2015
Mar 2023
total prescriptions.
HTN
TRX
NBRX new to brand prescriptions. HFrEF-heart failure with reduced ejection fraction. HF heart failure.
hypertension. SOC standard of care. 1. IQVIA National Prescription Audit.
2. CHF market basket includes ACEI, ARB, SGLT2i, Entresto. Data refers to US. 3. Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients
with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US), HFrEF (EU), HFrEF and HTN (China) and CHF and HTN (JP). HTN is not an approved indication in the US. 4. For forecasting purposes, we assume no
generic entry in US before 2025. 5. AHA/ACC/HFSA/ESC. 6. If approved, pediatric indication would support extension of the regulatory data protection to November 2026 in EU.
12 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation